Inhibitory effects of Celecoxib and Sc-58125 on proliferation of human carcinoma of larynx Hep-2in vitro

Abstract

The inhibitory effects of two kinds of selective cyclooxygenase-2 inhibitors on the proliferation of human carcinoma of larynx Hep-2in vitro and their corresponding mechanisms were investigated. Hep-2 cells were cultured with two kinds of selective cyclooxygenase-2 inhibitors (Sc-58125 and Celecoxib) at various concentration for 24 h. Morphological changes were observed under the phase microscopy and the growth suppression was detected by using MTT colorimetric assay. Apoptotic DNA fragments were observed by agarose gel electrophoresis and the cell cycle and apoptotic rate were detected by flow cytometry (FCM) respectively. Hep-2 cells became rounded and detached from the culture dish after being treated with Celecoxib for 24 h, however, they remained morphologically unchanged with Sc-58125. Sc-58125 could increase G₂ phase cells, whereas, Clecoxib rose G₁ phase cells. Both of the two effects were dose-dependent. Moreover, the Hep-2 cells cultured with 50μmol/L and 100μmol/L Celecoxib showed obvious apoptosis, with the nuclear DNA of cells exhibiting characteristic DNA ladder. So Sc-58125 could inhibit the proliferation of Hep-2 cells by altering the G₂ phase cells. However, Celecoxib had the same effect by changing the G₁ phase cells and inducing apoptosis at higher concentration.

Keywords

Sc-58125 / Celecoxib / carcinoma of larynx / Hep-2 cell / Inhibition / proliferation

References

[1] JaeckelE C, RajaS, TanJ, et al. . Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor δwith head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg, 2001, 127(10): 1233-1233

[2] FanJ, DouK F, LiK Z. Inhibitory effects of celecoxib on proliferation of human liver and gastric carcinoma cellsin vitro. Shi Jie Hua Ren Xiao Hua Za Zhi (Chinese), 2004, 12(3): 523-523

[3] CooganP F, RosenbergL, PalmerJ R, et al. . Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev, 2000, 9(1): 119-119

[4] MorrisC D, ArmstrongG R, BigleyG, et al. . Cyclooxygenase-2 expression in the Barrett’s metaplasia-dysplasia-adenocarcinoma sequence. Am J Gastroenterol, 2001, 96(4): 990-990

[5] FeldmanM, McMahonA T. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?. Ann Intern Med, 2000, 132(2): 134-134

[6] LiuJ S. Cellular Signaling and Modulation (Chinese), 1998, Beijing, Beijing Medical University and China Xiehe Medical University Press: 287-287

[7] XuM H, WuK C, WuH P, et al. . The inhibitory effect of nonsteroid anti-inflammatory drugs on gastric cancer. Chin J Dig, 2002, 22(4): 199-199

[8] GroschS, TegederI, NiederbergerE, et al. . COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cell by the selective COX-2 inhibitor celecoxib. FASEB J, 2001, 15(14): 2742-2742

[9] WilliamsC S, ShengH, BrockmanJ A, et al. . Acyclooxygenase-2 inhibitor (Sc-58125) blocks growth of established human colon cancer xenografts. Neoplasia, 2001, 3(5): 428-428